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Background: Ivacaftor is used to treat patients with CF and a G551D gating mutation; the KONNECTION study assessed the efﬁcacy and safety of
ivacaftor in patients with CF and a non-G551D gating mutation.
Methods: Patients with CF≥6 -years- old with non-G551D gating mutations received ivacaftor 150 mg q12h or placebo for 8 weeks in this 2-part,
double-blind crossover study (Part 1) with a 16-week open-label extension (Part 2). The primary efﬁcacy outcome was absolute change in FEV1
through 8 and 24 weeks of ivacaftor treatment; secondary outcomes were changes in BMI, sweat chloride, and CFQ-R and safety through 8 and
24 weeks of treatment.
Results: Eight weeks of ivacaftor resulted in signiﬁcant improvements in percent predicted FEV1, BMI, sweat chloride, and CFQ-R scores that
were maintained through 24 weeks. Ivacaftor was generally well tolerated.
Conclusions: Ivacaftor was efﬁcacious in a group of patients with CF who had selected non-G551D gating mutations.
© 2014 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Ivacaftor; Gating mutation; Potentiator; G551D1. Introduction
Cystic fibrosis (CF) is an autosomal recessive genetic disease
caused by mutations in the cystic fibrosis transmembrane
conductance regulator (CFTR) gene [14,17]. These mutations
result in a lack of functional CFTR protein or dysfunctional
CFTR protein channels at the surface of epithelial cells, which
causes impaired chloride transport, dysregulated fluid balance,
and thickened mucosal secretions in organ systems such as the⁎ Corresponding author at: University Hospital, Gasthuisberg, CF Reference
Centre, Herestraat 49, 3000 Leuven, Belgium.
E-mail address: Christiane.DeBoeck@uzleuven.be (K. De Boeck).
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1569-1993/© 2014 European Cystic Fibrosis Society. Published by Elsevier B.V. Alungs, pancreas, sweat glands, and reproductive organs [1,16].
Most available treatments for CF address the symptoms and
sequelae of the disease rather than the underlying molecular
pathophysiology [8,11].
To date, more than 1,900 mutations in the CFTR gene have
been identified [5]. Molecular characterization of the CFTR
mutations has led to classification according to whether the
functional defect impacts CFTR protein production, trafficking,
function, or stability [2,17]. The opening and closing functions
of the CFTR channel, termed gating, are mostly due to con-
formational changes to the channel driven by ATP binding and
hydrolysis in the channel's cytosolic nucleotide-binding domains
[10]. Class III mutations limit ATP-dependent channel gating,
resulting in loss of CFTR-dependent chloride transport [17,21].ll rights reserved.
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accounts for approximately 4% of the CF population worldwide
[19]. Other mutations that reduce CFTR channel gating include
G178R, S549N, S549R, G551S, G970R, G1244E, S1251N,
S1255P, and G1349D; however, these mutations are very rare,
jointly accounting for approximately 1% of patients with CF [2].
As for many other CFTR mutations, large regional differences in
the occurrence of these mutations have been documented [7].
One approach to increasing chloride transport in cells with
gating mutations is to use a CFTR potentiator, which is a com-
pound that increases the open probability of CFTR channels at
the cell surface [18,21]. In vitro studies showing that ivacaftor
improves chloride transport in cells expressing the G551D
mutation [18] led to clinical studies demonstrating the efficacy
and safety of ivacaftor in patients with this mutation [6,13].
Subsequently, ivacaftor was approved for the treatment of CF in
patients≥6 years of age with aG551Dmutation. However, there
is evidence to suggest that other patients with CF may benefit
from ivacaftor treatment as well. In vitro research has shown
that ivacaftor potentiates chloride transport in cells expressing
non-G551D gating mutations, including G178R, S549N, S549R,
G551S, G970R, G1244E, S1251N, S1255P, and G1349D [21].
Therefore, it was hypothesized that ivacaftor would potentiate
chloride transport and improve clinical outcomes in a genetically
diverse group of patients with CF who carry one of these
non-G551D gating mutations.
2. Materials and methods
2.1. Study design
KONNECTION (VX12-770-111) was a 2-part, randomized,
controlled study to evaluate the safety and efficacy of ivacaftor
in patients with CF ≥6 -years-old with a non-G551D gating
mutation on at least one allele (ClinicalTrials.gov identifier
NCT01614470). This was an international multi-center study of
12 sites in the United States, France, and Belgium. Part 1 of the
study was an 8-week, double-blind, placebo-controlled cross-
over study including a 4-to-8-week washout period. Part 2 was
an open-label extension period designed to assess the durability
of any observed treatment effects through 24 weeks of
continuous treatment (Supplemental Figure S1).
In Part 1, eligible patients were randomized 1:1 to 1 of 2
treatment sequences: ivacaftor 150 mg q12h for 8 weeks followed
by placebo q12h for 8 weeks (sequence 1, ivacaftor → placebo)
or placebo q12h for 8 weeks followed by ivacaftor 150 mg
q12h for 8 weeks (sequence 2, placebo → ivacaftor). In Part 2 of
the study, all patients received ivacaftor 150 mg q12h for
16 weeks. Thus, patients randomized to treatment sequence 1
(ivacaftor → placebo) had a maximum of 16 weeks of contin-
uous ivacaftor treatment; patients randomized to treatment se-
quence 2 had a maximum of 24 weeks of continuous ivacaftor
treatment.
The study was conducted in compliance with Institutional
Review Board regulations, Good Clinical Practice guidelines,
and the Declaration of Helsinki. All patients provided written
informed consent or assent, as appropriate.2.2. Study population
Male and female patients who were ≥6 -years-old and had a
confirmed diagnosis of CF [15] and the presence of one of
the following CFTR mutations on ≥1 allele were eligible for
inclusion: G178R, S549N, S549R, G551S, G970R, G1244E,
S1251N, S1255P, or G1349D. Patients must have had an
FEV1 ≥40 percent of predicted at screening, based on the
Hankinson standard [9] for males ≥18 years and females
≥16 years of age, or the Wang standard [20] for males 6 to
17 years of age and females 6 to 15 years of age. There was no
upper limit for percent predicted FEV1 at screening. Exclusion
criteria included the presence of the G551D mutation and the
use of inhaled hypertonic saline, which was not an approved
therapy at the time of this study.
2.3. Outcome measures
In Part 1, the primary outcome measure was the absolute
change from baseline in percent predicted FEV1 through
8 weeks of ivacaftor treatment. Secondary outcome measures
included the absolute change from baseline in BMI at 8 weeks
of treatment; sweat chloride through 8 weeks of treatment
(evaluated using a Macroduct® [Wescor, Logan, UT] collection
device; samples were sent to a central laboratory for testing
[quantification by coulometric titration]); and respiratory
domain score of the Cystic Fibrosis Questionnaire-Revised
(CFQ-R) [12] through 8 weeks of treatment.
In Part 2, the primary outcome measure was the absolute
change from baseline in percent predicted FEV1 through 24
consecutive weeks of ivacaftor treatment, which was obtained
from patients in treatment sequence 2 only (8 weeks in Part 1,
period 2, plus 16 weeks in Part 2). Secondary outcome measures
included the absolute change from baseline in BMI at 24 weeks
of treatment, sweat chloride through 24 weeks of treatment, and
the respiratory domain score of the CFQ-R through 24 weeks of
treatment.
Safety and tolerability were assessed throughout the study
using AE reports, clinical laboratory values for serum chemistry,
hematology, and coagulation, ophthalmologic examinations,
electrocardiograms (ECGs), and vital signs. Pulmonary exacer-
bations, as previously defined, were also evaluated [13].
2.4. Statistical analyses
The full analysis and safety sets included all patients ran-
domized to treatment groups who received at least 1 dose of
study drug. In Part 1, the analyses for the absolute change in
percent predicted FEV1, sweat chloride, and CFQ-R were based
on a mixed-effects model for repeated measures (MMRM). The
model included the absolute change from the baseline in each
treatment period as the dependent variable, with sequence,
treatment, period, and visit within period as fixed effects, study
baseline (for the measure) and age as covariates, and patient
nested within sequence as the random effect. The absolute
change from baseline in BMI was analyzed using a linear
mixed model (LMM), with sequence, period, and treatment as
Table 1
Demographic and baseline characteristics, full analysis set.
Ivacaftor → Placebo
(n = 20)
Placebo → Ivacaftor
(n = 19)
Overall
(N = 39)
Sex, n (%)
Male 13 (65.0) 9 (47.4) 22 (56.4)
Female 7 (35.0) 10 (52.6) 17 (43.6)
Geographic region, n (%)
North America 11 (55.0) 11 (57.8) 22 (56.4)
Europe 9 (45.0) 8 (42.1) 17 (43.6)
Age, y
Mean 23.8 21.7 22.8
Range 6-57 6-47 6-57
FEV1, % predicted
Mean 77.7 79.1 78.4
Range 43.0 to 118.7 42.9 to 104.1 42.9 to 118.7
Weight-for-age z-score
Mean 0.379 −0.182 0.084
Range −1.966 to 2.286 −1.457 to 1.480 −1.966 to
2.286
Height-for-age z-score
Mean −0.096 −0.799 −0.466
Range −2.488 to 1.281 −2.555 to 0.378 −2.555 to
1.281
BMI-for-age z-score
Mean 0.503 0.229 0.359
Range −1.593 to 2.264 −1.462 to 1.647 −1.593 to
2.264
Sweat chloride, mmol/L
Mean 94.6 100.7 97.5
Range 12.0 to 118.0 75.5 to 121.5 12.0 to
121.5
F508del mutation,
n (%)
10 (50.0) 14 (73.7) 24 (61.5)
Pancreatic
insufficiency
14 (70.0) 17 (89.5) 31 (79.5)
Note: BMI = body mass index.
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interaction as random effects, and adjustment for study baseline
age and percent predicted FEV1 as covariates; visit was treated
as a continuous variable. The absolute changes from baseline in
percent predicted FEV1 (at 2, 4, and 8 weeks) and BMI, sweat
chloride, and CFQ-R (at 8 weeks) were compiled by genotype.
In Part 2, the absolute change from baseline in percent
predicted FEV1 through 24 weeks of treatment for patients
originally randomized to placebo was defined as the average of
non-missing measurements after 2, 4, 8, 16, and 24 weeks of
treatment. Secondary outcome measures in Part 2 were also
summarized.
3. Results
3.1. Patients
Thirty-nine patients were enrolled and randomized to
treatment groups; in Part 1, 20 patients were randomized to
treatment sequence 1 (ivacaftor → placebo) and 19 to treat-
ment sequence 2 (placebo → ivacaftor; Supplemental Figure
S2). At baseline, defined as the measure closest to but before
the first dose of study drug, the mean age of patients was
22.8 years and the mean percent predicted FEV1 was 78.4
(Table 1). The majority of patients were white and not Hispanic
or Latino (28/39, 71.8%). The mean sweat chloride of patients
was high (97.5 mmol/L), and most patients were pancreatic
insufficient (79.5%). All baseline characteristics were similar
between treatment sequences and similar to G551D patient
populations (Table 1). Three patients discontinued treatment
during Part 1. One patient was lost to follow-up (sequence 2)
and 2 patients (1 in each sequence group) discontinued due to
the need for antibiotic therapy that extended the between-period
washout (classified as “other”). Eighteen patients from each
treatment sequence in Part 1 completed Part 2.
3.2. Efficacy
3.2.1. Part 1: Double-blind, 8-week crossover study
3.2.1.1. Overall. Patients receiving ivacaftor demonstrated a
significant (P b 0.0001) improvement in absolute percent
predicted FEV1 (7.5 percentage points) through 8 weeks of
treatment, whereas FEV1 declined in patients receiving placebo
(−3.2 percentage points; Fig. 1a). The model-adjusted absolute
mean treatment difference between the ivacaftor and placebo
groups was 10.7 percentage points (95% CI: 7.3, 14.1).
Statistically significant effects of ivacaftor treatment were also
observed at weeks 2 and 4 (P b 0.0001 at both time points)
when compared with placebo. The model-adjusted mean
differences between ivacaftor and placebo groups at weeks 2
and 4 were 8.3 percentage points (95% CI: 4.5, 12.1) and 10.0
percentage points (95% CI: 6.2, 13.8), respectively. Additional
analyses showed that the treatment sequence had no significant
impact on the observed effects (data not shown).
Improvements in response to ivacaftor treatment were also
observed in the model-adjusted mean changes from baseline inBMI, sweat chloride, and CFQ-R (Figs. 1b–d). The model-
adjusted absolute mean change from baseline in BMI at week 8
was greater during treatment with ivacaftor (0.7 kg/m2) com-
pared with placebo (0.02 kg/m2), resulting in a treatment
difference of 0.7 kg/m2 (95% CI: 0.34, 0.99; P b 0.0001;
Fig. 1b). Similarly, the model-adjusted mean absolute change
from baseline in BMI-for-age z-score showed a significant
improvement (0.24 points) at week 8 in ivacaftor-treated patients
compared with patients receiving placebo (−0.04 points),
resulting in a treatment effect of 0.28 points (95% CI: 0.12,
0.45; P = 0.0010).
The model-adjusted mean change from baseline in sweat
chloride through 8 weeks of treatment with ivacaftor was
−52.3 mmol/L compared with −3.1 mmol/L during the placebo
period (Fig. 1c). The resulting treatment effect was −49.2 mmol/L
(95% CI: −57.0, −41.4; P b 0.0001). Ivacaftor treatment led
to a significant decline in sweat chloride as early as week 2
(model-adjusted mean change, −48.2 mmol/L; 95% CI: −54.0,
−37.5; P b 0.0001) that was sustained through week 8.
The model-adjusted mean change from baseline in the pooled
(all questionnaire versions) CFQ-R respiratory domain score
through week 8 was significantly greater in patients treated with
ivacaftor (8.9 points) compared with patients receiving placebo
Fig. 1. Mean absolute change from baseline after 8 weeks of treatment in (A) percent predicted FEV1; (B) BMI; (C) sweat chloride; and (D) CFQ-R respiratory
domain score. BMI = body mass index; CFQ-R = Cystic Fibrosis Questionnaire-Revised.
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points (95% CI: 4.5, 14.7; P = 0.0004). The improvement
in CFQ-R score was observed as early as week 2 of ivacaftor
treatment (model-adjusted mean change, 6.1 points; 95% CI:
0.61, 12.8; P = 0.03). At week 8, 28/38 patients treated with
ivacaftor (73.7%) had an increase in CFQ-R score of ≥4 points,
which is considered to be the minimal clinically important
difference, compared with 11/37 patients (29.7%) on placebo.
3.2.1.2. By genotype. All genotype subgroups showed positive
mean numerical changes from baseline in BMI, CFQ-R score,
and FEV1 at week 8 of treatment (Table 2), with high variability
among and within subgroups. Mean changes in sweat chloride
were also similar among the genotype subgroups, with the
exception of the G970R subgroup, which showed a reduction in
sweat chloride that was markedly lower relative to the other
mutation subgroups.
3.2.2. Part 2: Open-label, 16-week extension study
All 36 patients who completed Part 1 of the study entered
Part 2 and completed the 16-week open-label extension study,
18 of whom are represented in the 24-week outcome measures.
The mean absolute change from baseline in percent predicted
FEV1 through week 24 of ivacaftor treatment was 13.5
percentage points (range, −6.9 to 36.5; Fig. 2). Examination
of secondary outcome measures revealed that the mean
absolute change from baseline in BMI at week 24 was 1.3 kg/
m2 (range, 0.16 to 2.9); the mean absolute change from baseline
in sweat chloride through week 24 was −59.2 mmol/L (range,−93.5 to 40.5); and the mean absolute change from baseline in
CFQ-R respiratory domain score was 11.4 (range, −16.7 to
33.3).
3.3. Safety
In Part 1, adverse events were reported by 83.8% (31/37) of
patients receiving placebo and 73.7% (28/38) of patients
receiving ivacaftor (Table 3). The most commonly reported
AEs in both treatment groups were infections, respiratory
disorders, and gastrointestinal disorders. Within the placebo
group, pulmonary exacerbations (11/37; 29.7%), cough (7/37;
18.9%), and headache (5/37; 13.5%) were the most commonly
reported AEs. The most commonly reported AEs in the
ivacaftor group were pulmonary exacerbation (9/38; 23.7%)
and cough (6/38; 15.8%). Seven patients (18.9%) in the placebo
group and 4 (10.5%) patients in the ivacaftor group experienced
serious AEs (SAEs). The SAEs were six pulmonary exacerba-
tions and one event each of appendiceal mucocoele, intussus-
ception, pneumothorax, and paranasal cyst in the placebo
group; and two pulmonary exacerbations, one distal ileal
obstruction syndrome event, and one intervertebral disc
protrusion event in the ivacaftor group.
During Part 2, AEs were reported by 83.3% (15/18) of
patients in either treatment sequence in part one (Table 3).
During the 16-week open-label extension, the most commonly
reported AEs overall were respiratory disorders, infections, and
gastrointestinal disorders. In the group continuing on ivacaftor,
the most commonly reported AEs were cough (3/18; 16.7%)
Table 2
Efficacy results, stratified by genotype, raw means.
Mutation, n Absolute change from baseline in % predicted FEV1, % points,
mean (min, max)
Absolute change from
baseline in sweat chloride
at week 8, mmol/L, mean
(min, max)
Absolute change from
baseline in BMI at
week 8, kg/m2,
mean (min, max)
Absolute change from
baseline in CFQ-R Score
at week 8, points,
mean 2(min, max)
At week 2 At week 4 At week 8
G1244E (5) 11.08 (−5.20, 25.41) 5.54 (−4.63, 12.95) 8.36 (−0.93, 18.37) −55.10 (−75.0, −34.0) 0.63 (0.34, 1.32) 3.3 (−27.8, 22.2)
G1349D (2) 19.42 (5.49, 33.36) 18.48 (1.60, 35.37) 19.67 (2.97, 36.37) −80.25 (−81.5, −79.0) 1.15 (1.07, 1.22) 16.7 (−11.1, 44.4)
G178R (5) 7.46 (1.42, 16.99) 10.23 (−2.31, 20.53) 8.37 (−0.77, 17.56) −52.50 (−64.5, −35.0) 0.85 (0.33, 1.46) 20.0 (5.6, 50.0)
G551S (2) −0.09 (−4.69, 4.51) 0.29 (−5.32, 5.89) 3.12 a −68.0 a 0.16 a 16.7 a
G970R (4) 6.72 (0.52, 12.61) 6.76 (1.21, 14.23) 2.55 (−1.30, 4.52) −6.25 (−16.0, −2.0) 0.48 (−0.38, 1.75) 1.4 (−16.7, 16.7)
S1251N (8) 2.14 (−23.28, 19.95) 7.66 (−13.20, 26.03) 8.70 (−19.57, 21.38) −54.38 (−84.0, −7.0) 0.73 (0.08, 1.83) 23.3 (5.6, 50.0)
S1255P (2) 11.10 (8.25, 13.94) 8.73 (4.74, 12.73) 3.14 (−1.42, 7.70) −77.75 (−82.0, −73.5) 1.62 (1.39, 1.84) 8.3 (5.6, 11.1)
S549N (6) 10.55 (5.11, 15.93) 8.06 (−9.29, 19.30) 11.31 (−2.40, 19.78) −74.25 (−92.5, −53.0) 0.79 (0.00, 1.91) 8.8 (−8.3, 27.8)
S549R (4) 3.47 (−3.55, 7.59) 4.11 (−3.78, 10.00) 5.18 (−3.07, 12.74) −60.67 (−70.5, −53.5) 0.53 (0.33, 0.80) 6.9 (0.0, 11.1)
Overall 7.23 (−23.28, 33.36)
(n = 38)
7.55 (−13.20, 35.37)
(n = 38)
8.13 (−19.57, 36.37)
(n = 37)
−55.82 (−92.5, −2.0)
(n = 36)
0.75 (−0.38, 1.91)
(n = 37)
12.31 (−27.8, 50.0)
(n = 37)
a Only one patient with the G551S mutation completed 8 weeks of ivacaftor treatment.
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monly reported AEs in the ivacaftor → placebo group were
headache (4/18; 22.2%) and pulmonary exacerbation (3/18;
16.7%). Overall, three patients reported six SAEs; there were
two cases of pulmonary exacerbations, and one case each of
dehydration, convulsion, dizziness, and distal ileal obstruction
syndrome. The mean normalized number of days with
pulmonary exacerbation in Part 2 was 1.87 in patients from
the placebo → ivacaftor group during Part 1, and 2.53 in the
group of patients who were in the ivacaftor → placebo group
in Part 1.4. Discussion
In the KONNECTION study, 8 weeks of treatment with
ivacaftor resulted in significant improvements in percent
predicted FEV1, BMI, sweat chloride, and CFQ-R respiratoryFig. 2. Mean absolute change from baseline in percent predicted FEV1 over
24 weeks of ivacaftor treatment for patients from treatment sequence 2
(placebo → ivacaftor).domain scores in patients with CF and a non-G551D gating
mutation. Improvements in percent predicted FEV1, sweat
chloride, and CFQ-R respiratory domain score were detectable
by week 2 of treatment and sustained through 8 weeks of
treatment; moreover, the results from the open-label extension
period supported the durability of improvements in lung
function through 24 weeks. Treatment with ivacaftor was
generally well tolerated; during Part 1, the number of reported
AEs and serious AEs was comparable in the placebo and
ivacaftor groups. The specific AEs reported throughout the
study were similar to those previously reported in STRIVE and
ENVISION—Phase 3 studies of ivacaftor in patients with CF
and the G551D-CFTR gating mutation [6,13].
Although the studies cannot be compared directly, the
treatment effects observed in the KONNECTION study were
similar in direction and magnitude to the treatment effects
reported in the STRIVE and ENVISION studies [6,13]. In
STRIVE and ENVISION, the effects of ivacaftor treatment on
percent predicted FEV1 through 24 weeks were 10.6 and 12.5
percentage points, respectively. In KONNECTION, the effect
of ivacaftor treatment through 8 weeks was 10.7 percentage
points. These similarities among clinical studies are encourag-
ing given the large number of CFTR mutations that have been
identified and the unmet medical need for treatments that
improve outcomes in very small patient populations. The
ability to make predictions about response based on knowledge
regarding the functional consequences of a mutation will be
important in the future and underscores the importance of
personalized medicine for the CF community [2].
The examination of efficacy outcomes according to CFTR
gating mutation indicated that there were varying degrees of
clinical improvement after 8 weeks of treatment with ivacaftor.
Sample sizes for each mutation were extremely small, so
conclusions about the relative efficacy of ivacaftor by genotype
should not be drawn at this stage; some genotype subgroups
included as few as two patients, and intraindividual variability
in these clinical measures is expected. In this study, there was
no upper limit to FEV1 as an entry criterion; in some patients, a
ceiling effect may be present. However, while the mean
Table 3
Adverse events.
Part 1 Part 2
Placebo
(n = 37)
n (%)
Ivacaftor
(n = 38)
n (%)
Placebo → Ivacaftor
(n = 18)
n (%)
Ivacaftor → Placebo
(n = 18)
n (%)
Patients with adverse events, n (%) 31 (83.8) 28 (73.7) 15 (83.3) 15 (83.3)
Patients with serious adverse events, n (%) 7 (18.9) 4 (10.5) 0 3 (16.7)
Patients with adverse events leading to discontinuation 0 0 0 0
Adverse events occurring in ≥15% of patients in any group
Infective pulmonary exacerbation of cystic fibrosis 11 (29.7) 9 (23.7) 3 (16.7) 3 (16.7)
Cough 7 (18.9) 6 (15.8) 3 (16.7) 2 (11.1)
Headache 5 (13.5) 3 (7.9) 0 4 (22.2)
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in other small subgroups, there were much smaller sweat
chloride responses in these individuals relative to the other
genotype subgroups studied. Additional studies will be required
to elucidate the effects of ivacaftor in patients with the G970R
mutation, which is complicated by the fact that there are fewer
than a dozen known individuals with this mutation worldwide
[4]. Notwithstanding the G970R mutation (which showed an in
vitro response comparable to other gating mutations), in vitro
studies have accurately predicted patient response to ivacaftor
treatment in 8 of the 9 gating mutations tested. For instance, in
vitro results were predictive of the positive clinical results in the
ivacaftor Phase 3 studies of patients with the G551D mutation
([18,6,13]. Likewise, the negative clinical results in patients
who are homozygous for the F508del mutation was predicted
by in vitro data [3,21].These examples, together with the results
of this study, support the continued use of these in vitro models.
The KONNECTION study illustrates the utility of a
non-traditional approach to Phase 3 clinical study design
(crossover vs. parallel-group) that may be useful for therapeutic
areas with ultra-rare patient types; using a crossover design
with an open-label extension allowed both a within-subjects
analysis and longer-term evaluation of ivacaftor, whereas a
more typical parallel-group design would not have provided
adequate statistical power in this small population. In the
future, “N of 1” trials may be considered for even rarer
genotypes. Moreover, this study illustrates the importance of
using in vitro models that accurately characterize a mutation or
patient group in a manner that predicts clinical response to a
treatment.
The KONNECTION study demonstrates that patients with
CF who have selected non-G551D gating mutations show
clinical and pharmacodynamic improvements in response to
treatment with ivacaftor that are similar to the benefits observed
in patients with CF who have a G551D gating mutation. The
findings in KONNECTION support grouping patients on the
basis of knowledge about the functional consequences of their
mutation types, and underscore the importance of developing in
vitro models that can aid in the accurate characterization of
mutation types. Continued global cooperation among cell
biologists, physicians, patients, and registries may build onthis progress to help ensure that ultra-rare mutation types can
become better understood and appropriate care made available
to greater numbers of patients with CF.Disclosures and acknowledgments
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